Overview
How Should I Treat AChR-Ab Seronegative gMG? Weighing The Latest Evidence to Inform Precision-Based Care
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
No two patients with generalized myasthenia gravis (gMG) are the same and individualizing treatment is vital. Clinicians must integrate factors such as age of onset, autoantibody profile, clinical manifestation, gender, and thymic pathology to classify gMG subtypes and tailor treatment strategies. The treatment armamentarium has also recently expanded with novel agents and expanded indications, further complicating decisions.
To help clinicians interpret and apply the growing body of evidence in treatment selection across gMG subtypes, this point-counterpoint digital activity uses case-based discussions to frame differing perspectives around complex clinical questions, helping learners align their diagnostic approaches and treatment decisions with available evidence.
Through the point-counterpoint exchange, faculty will discuss the following:
• At what point should electrophysiology testing be pursued for a differential diagnosis?
• When should AChR or MuSK serology be retested?
• What is the role of newer, more sensitive testing approaches?
• What patients may benefit from an FcRn-targeting therapy vs conventional treatment?
• How do factors such as dosing frequency, route of administration, and patient preference weigh on selection of an FcRn-targeting therapy?
This activity is intended for neurologists, neuromuscular specialists, and advanced practice providers in the specialty setting.
Upon completion of this activity, learners will be able to:
• Discuss the clinical burden of generalized myasthenia gravis (gMG)
• Outline the steps for diagnosing gMG and the importance of determining autoantibody status
• Interpret the latest clinical trial data supporting the efficacy and safety of neonatal Fc receptor (FcRn) inhibitors
• Formulate individualized treatment for patients with MuSK antibody positive, LRP-4 antibody positive, and triple seronegative MG
• Discuss the clinical burden of generalized myasthenia gravis (gMG)
• Outline the steps for diagnosing gMG and the importance of determining autoantibody status
• Interpret the latest clinical trial data supporting the efficacy and safety of neonatal Fc receptor (FcRn) inhibitors
• Formulate individualized treatment for patients with MuSK antibody positive, LRP-4 antibody positive, and triple seronegative MG
Provided by the Academy for Continued Healthcare Learning (ACHL).
This activity is supported by an educational grant from argenx US Inc.
Christyn Edmundson, MD
Director of Neuromuscular Medicine
Swedish Neuroscience Institute
Seattle, WA
Director of Neuromuscular Medicine
Swedish Neuroscience Institute
Seattle, WA
Karissa Gable, MD
Professor of Neurology
Duke University
Durham, NC
Chafic Karam, MD
Professor of Neurology
Chief, Neuromuscular Division
Department of Neurology
University of Pennsylvania
Philadelphia, PA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Christyn Edmundson, MD
Speakers' Bureau: Alexion, Alnyulam, Amgen, argenx, UCB
Karissa Gable, MD
Consulting Agreements: argenx, CSL Behring, Dianthus, Grifols, Immunovant, Sanofi, Takeda
Chafic Karam, MD
Sources of Funding for Research:
Planning Committee Member, Moderator: Consulting Agreements: argenx, AstraZeneca, CSL Behring, Dianthus, GenSci, Grifols, IM, Keyverna, Nuvig, Sanofi, Takeda
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: intravenous or subcutaneous immunoglobulin, plasma exchange, rituximab, corticosteroids, and other immunosuppressive agents such as azathioprine, mycophenolate mofetil, and cyclosporin
To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Partial credit may not be awarded for CPE/CBRN/IACET credit; participation in the complete activity is required to receive credit
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
